Details

Last Funding Type

Series C

Last Funding Money Raised

€33.70M

Industries

Biopharma,Biotechnology,Pharmaceutical

Founded date

Jan 1, 2001

Number Of Employee

11 - 50

Operating Status

Close

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.